Opexa Therapeutics (OPXA) Surges on FDA Fast-Track Designation for Tovaxin
Tweet
Share
E-mailGet Alerts OPXA Hot Sheet
Join SI Premium – FREE
Opexa Therapeutics, Inc. (NASDAQ: OPXA) is surging higher in pre-open trading Tuesday after the company said lead drug candidate Tovaxin has been granted Fast Track designation by the FDA for the treatment of patients with Secondary Progressive Multiple Sclerosis (SPMS).
Shares last traded at $1.45, up 40 percent from Monday's close.
Shares last traded at $1.45, up 40 percent from Monday's close.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Texas Instruments (TXN) jumps on first above-consensus guide in seven years
- Enphase Energy tumbles on guidance miss; BMO trims estimates and price target
- Kiromic BioPharma (KRBP) Reports Consistent Favorable Safety, Tolerability, and Efficacy in Deltacel-01 Trial First Three Patients
Create E-mail Alert Related Categories
FDA, Momentum MoversSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
